Table 1.
Characteristics of included studies by proportion (percentage), unless otherwise specified
| Characteristics | Proportion |
| Study design | |
| Publication type: | |
| Preprint | 11/63 (17) |
| Journal article | 52/63 (83) |
| English language | 63/63 (100) |
| Median sample size (interquartile range) | 72 729 participants (1106-527 856) |
| Median follow-up (interquartile range) | 27.6 weeks (19.6 to 48.0) |
| Setting | |
| Country classification (World Bank): | |
| High income | 60/63 (95) |
| Upper middle income | 3/63 (5) |
| Lower middle income | 0/63 (0) |
| Low income | 0/63 (0) |
| Year of study*: | |
| 2018 | 1/63 (2) |
| 2019 | 5/63 (8) |
| 2020 | 57/63 (90) |
| 2021 | 35/63 (56) |
| 2022 | 6/63 (10) |
| Sampling: | |
| Convenience | 60/63 (95) |
| Probabilistic | 3/63 (5) |
| Recruitment†: | |
| Community/contact tracing | 29/63 (46) |
| Outpatient | 31/63 (49) |
| Hospital | 39/63 (62) |
| Intensive care unit | 15/63 (24) |
| Data collection†: | |
| Administrative data | 34/63 (54) |
| Clinical assessment | 9/63 (14) |
| Survey (unspecified) | 10/63 (16) |
| Online survey | 6/63 (10) |
| Phone survey | 3/63 (5) |
| Population: | |
| Younger adults (19-44 years) | 49/63 (78) |
| Middle age group (45-65 years) | 56/63 (89) |
| Older adults (>65 years) | 53/63 (84) |
| Gender: | |
| Male | 62/63 (98) |
| Female | 63/63 (100) |
| Other | 2/63 (3) |
| Reported circulating variant: | |
| Not reported | 57/63 (90) |
| Alpha or wildtype | 4/63 (6) |
| Omicron/delta | 2/63 (3) |
| Severity: | |
| Mild | 28/63 (44) |
| Moderate | 23/63 (36) |
| Severe | 26/63 (41) |
| Critical | 10/63 (16) |
| Included reinfected participants | 3/63 (5) |
| Included vaccinated participants | 12/63 (19) |
| Reported socioeconomic status | 28/63 (44) |
| Prognostic factors: | |
| Symptoms/onset | 19/63 (30) |
| Severity/infection | 31/63 (49) |
| Vaccination status | 9/63 (14) |
| Gender | 48/63 (76) |
| Race/ethnicity | 18/63 (29) |
| Socioeconomic status | 17/63 (27) |
| Comorbidities | 48/63 (76) |
| Non-communicable diseases | 34/63 (54) |
| Immunosuppression | 17/63 (27) |
| Outcomes: | |
| Health related quality of life | 14/63 (22) |
| Functioning | 10/63 (16) |
| Medical and rehabilitation needs | 24/63 (38) |
| Recovery rates | 19/63 (30) |
| Incident medical diagnosis | 33/63 (52) |
*Some studies included participants during several years (including cohorts before the pandemic), leading to more than 100% overall here.
†Some studies used several sources for recruitment and data collection, leading to more than 100% overall here.